Genmab (0MGB)

2,948.00
+42.50(+1.46%)
  • Volume:
    3,772
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    2,948.00 - 2,948.00

0MGB Overview

Prev. Close
2,905.5
Day's Range
2,948-2,948
Revenue
-
Open
2,915
52 wk Range
1,914.5-3,097
EPS
-
Volume
3,772
Market Cap
190.27B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
10,924
P/E Ratio
73.75
Beta
-
1-Year Change
24.86%
Shares Outstanding
65,385,847
Next Earnings Date
03 Nov 2021
What is your sentiment on Genmab A/S?
or
Market is currently closed. Voting is open during market hours.

Genmab A/S News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Genmab A/S Company Profile

Genmab A/S Company Profile

Sector
Services
Employees
1029
Market
Denmark

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.